Cortice begins patient enrolment in Phase I trial of TPI 287 to treat rare tauopathy diseases

US-based Cortice Biosciences has initiated enrolling patients in a Phase I trial of its lead drug candidate, TPI 287, for treatment of patients with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news